CONFERENCE DAY ONE
TUESDAY, JULY 23

8.00 Registration & Morning Coffee

8.50 Chairperson’s Opening Remarks

The Next Frontier in Cancer Innovation - the Human Microbiome

Session Purpose:
As our understanding of the human microbiome matures, there has been an injection of scientific interest and investment into the microbiome-oncology intersection. The cancer community is realizing the next wave of innovation through microbiome-based approaches that improve patient stratification and response to already existing cancer therapies. This theme will highlight the new opportunity set into motion by the collision of microbiome and cancer research.

9.00

Leveraging Gut Microbiota Networks for Impacting Tumor
Immunotherapy

• Discovering the concept of “reverse translation” as a strategy for microbiome drug discovery - identification of a microbiome signature and its association with treatment and response
• Using mouse tumor models to validate clinical observations and to optimize microbiome therapies
• Seeing the value of partnering with investigators in premier academic institutions and industry to rapidly bring microbiome therapies to patients

Christopher Ford
Director, Microbiome Sciences
Seres Therapeutics

Microbial Dysbiosis in Cancer – Cause or Consequence?

Session Purpose:
Early research has suggested that the microbiome is a contributing causal factor of carcinogenesis but it is unclear to what extent this is the case. It is also unclear whether the tumor microenvironment has a mechanistic role in microbial dysbiosis. This theme will explore evidence for both the causal and consequential interactions between the tumorigenic environment, the immune system and the microbiome.

9.30

Exploring the Role of the Intestinal Microbiome in Allogeneic Hematopoietic Cell Transplantation

• Demonstrating that patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) incur rapid changes in their intestinal microbiota
• Demonstrating that these changes in the intestinal microbiota are associated with clinically relevant outcomes in patients undergoing allo-HCT including overall survival and lethal graft-versus-host disease

Jonathan Peled, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center

 

 

10.00

Examining the Microbes & Immune Cells Instrumental in Potentiating Carcinogenesis

Wendy Garrett
Professor of Immunology & Infectious Diseases
Harvard T.H. Chan School of Public Health

10.30 Speed Networking & Morning Refreshments

11.30

Revealing How Microbiota Controls Inflammation & Cytokines to Promote Colon Cancer

• Exploring how tumor adhesive microbiota stimulate intra-tumoral immune cells
• Demonstrating that the cytokines produced by immune cells in microbiotadependent manner regulate immunity and tumor promotion
• Highlighting how the effects of microbiota-driven cytokines within the tumor microenvironment may be cell type specific

Sergei Grivennikov
Assistant Professor
Fox Chase Cancer Center

12.00

Enhancing Anti-Tumor Immunity via Targeted Alteration of the Microbiome

• Developing a clinical program to study microbiome and checkpoint inhibitor success
• Discussing how to get the clinical networking in place in order to collect and analyze stool sample data
• Complementary approaches in preclinical models to address microbiome and anti-tumor immunity

Fyza Shaikh, MD
Postdoctoral Fellow
John Hopkins Hospital

 

 

Integrating –Omics Data to Understand Causality of the Microbiome in Cancer

Session Purpose:
Light years of progress have been made in terms of genomic characterization of microbes. However, there remains a gap in understanding how to analyze metagenomic, proteomic and pharmacomicrobiomic data and integrate it with clinical data. The purpose of this session will be to explore how we can maximize the knowledge gained from –omics data and how to use it to inform clinical decision making in the cancer setting.

12.30

Revolutionizing Dogmas Through Oncobiome Science

• Overviewing recent progress in understanding the gut microbiome and its relationship with cancer therapy
• Highlighting the recent discovery and utilization of the commensal (tissue) microbiome’s impact on cancer’s initiation, progression, and treatment resistance
• Discussing the implications of these findings and technological approaches to developing microbially-sensitive cancer diagnostics, prognostics, and therapeutics

Gregory Poore
MD/PhD Candidate
UC San Diego, Center for Microbiome Innovation

 

 

13.00 Lunch & Networking

Understanding the Role of Nutrition in Cancer Treatment & Prevention

Session Purpose:
Whilst the majority of applications of the microbiome in cancer focus on its curative potential, there is a significant amount of research being done into understanding its preventative role and as a nutritional intervention. This theme will showcase the early clinical and pre-clinical work investigating how the microbiome can be used to treat and prevent cancer.

14.00

Exploring Diet, the Microbiome & Response to Immunotherapy

• Understanding how a high fiber diet is associated with improved response to immunotherapy
• Revealing how the gut microbiome can be modulated through dietary interventions
• Demonstrating that probiotics are associated with a lower diversity of the gut microbiome

Jennifer McQuade, MD
Assistant Professor
MD Anderson Cancer Center

14.30

Exploring Marine Omega-3 Fatty Acid & Colorectal Cancer Prevention & Treatment: The Role of the Gut Microbiome & Tumor Immunity

• Protecting against colorectal cancer through higher intake of marine omega-3 fatty acid
• Supporting the benefit of marine omega-3 fatty acid for colorectal cancer survival through epidemiologic evidence
• Addressing how these benefits may be mediated by modulation of the gut microbiome and tumor immunity

Mingyang Song, MD
Assistant Professor
Massachusetts General Hospital and Harvard Medical School

 

 

Identifying Microbial Profiles as Prognostic Biomarkers & Defining Considerations for Live Biotherapeutic Product Development

Session Purpose:
One application of the microbiome in cancer is through the use of microbiome-based live biotherapeutic products (LBPs). The development of LBPs goes hand in hand with the identification of defined microbial signatures as prognostic biomarkers that can be used to identify (non)-responders to cancer therapies. This theme will explore how the microbiome is being used as a biomarker of response to cancer treatment and how the microbiome itself, can be harnessed to treat cancer.

15.00

Applying Microbiotica’s Platform to Modulate Cancer Immunotherapy Response & Identify Bacterial Biomarkers & Medicines

Trevor Lawley
Chief Scientific Officer & Co-Founder
Microbiotica

15.30 Afternoon Refreshments & Networking

16.00

Enhancing Anti-Tumor Immunity via Targeted Alteration of the Microbiome

• Leveraging translational medicine data and pre-clinical findings to generate rationally-designed consortia that augment anti-tumour immunity

Bruce Roberts
Chief Scientific Officer
Vedanta Biosciences

 

16.30

Into the Clinic: Challenges & Opportunities

• Manufacturing: DIY or outsourcing – the pros and cons
• Clinical trial design: the successful protocol – adding in the factors to demonstrate effect of LBPs
• Microbiome analysis: so much data, so little time - managing the analysis

Alex Stevenson
Chief Scientific Officer
4D Pharma

16.00

Focusing on Human-First Discovery: A Model for Translatable Drug Discovery in Microbial Therapeutics

• Developing both full-spectrum microbiota and rationally-selected microbiota products permits the development of therapies that are optimized for a given disease biology
• Understanding how clinical interventional data are a powerful tool for deconvoluting metagenomic datasets and identifying clinically relevant microbial strains
• Selecting strains for LBP consortia from clinically-demonstrated strains greatly mitigates translational risk and accelerates development timelines

Sonia Timberlake
Head of Research
Finch Therapeutics

 

 

 

17.30 Chairperson’s Closing Remarks

17.40 Close of Conference Day One